GEN Exclusives

More »

GEN News Highlights

More »
Sep 7, 2010

Ipsen Acquires Santhera’s Parkinson Drug for €13M Up Front

  • Santhera Pharmaceuticals received €13 million (about $16.58 million) from Ipsen under a potentially €141 million (about $179.75 million) deal granting the latter rights to fipamezole outside the U.S., Canada, and Japan. The compound is being developed as a treatment for levodopa-induced dyskinesia in Parkinson disease.

    While Santhera holds Japanese rights, Biovail owns the drug in the U.S. and Canada. Biovail expects to begin the Phase III program for fipamezole in 2011. Santhera’s agreement with Ipsen stipulates that Ipsen has the right to use the resulting data for its own development and commercialization purposes within its licensed territories.

    Additional payments contingent to future development, regulatory, and sales milestones of up to €128 million have also been agreed to. In addition, Santhera is entitled to royalty payments on Ipsen’s future net sales.

    Fipamezole is an antagonist of the adrenergic alpha-2 receptor that reportedly has a novel mode of action in the treatment of dyskinesia in Parkinson disease. The rationale behind development is to increase noradrenergic release in certain areas of the brain resulting in rebalancing of the brain network and potentially alleviating symptoms of advanced Parkinson disease, such as dyskinesia and motor fluctuations, without exacerbating the underlying Parkinsonian features of the disease.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »